A panel with
Giulia Bortolussi, ricercatrice ICGEB
Nicola Brunetti-Pierri, principal investigator Istituto Telethon di Genetica e Medicina, docente di Pediatria Università Federico II Napoli
Federico Mingozzi, Chief Executive Officer Newco
Andrés Muro, responsabile Laboratorio di Genetica Molecolare Murina ICGEB
Abstract
Treating genetic diseases by correcting the gene mutations that cause them is one of the most promising challenges in medicine today. This includes approaches like the use of viral vectors and gene-editing tools such as CRISPR/Cas9. How do basic and translational research contribute to the application of these therapies in clinical practice? Which approach is better suited for personalized medicine? We'll discuss these questions with the authors of the first clinical demonstration of the effectiveness of a gene therapy for the extremely rare Crigler-Najjar syndrome, a liver disease, published in the New England Journal of Medicine.